地西他滨在恶性血液肿瘤治疗中的应用  

Application of decitabine in the treatment of hematological malignancies

作　　者：周冰(综述)[1] 马梁明 梁立新(审校)[1] 

机构地区：[1]河南省三门峡市中心医院血液科,472000 [2]山西大医院血液科

出　　处：《肿瘤研究与临床》2013年第2期136-138,共3页Cancer Research and Clinic

摘　　要：地西他滨（DAC）是一种甲基化抑制剂，其不同于传统的化疗药物，具有独特的作用机制，并代表了新的治疗观念。甲基化存在于几乎所有的细胞内，通过抑制DNA甲基转移酶，引起DNA低甲基化和细胞分化或凋亡来发挥抗肿瘤作用。现就甲基化抑制剂DAC在恶性血液肿瘤治疗方面的应用进行综述。Decitabine is a methylation inhibitor, which is different from traditional chemotherapy drugs, with new and unique mechanism of action, and represent a new therapeutic concept. Methylation present in almost all cells, by inhibiting DNA methyltransferase, causing hypomethylation of DNA and cell differentiation or apoptosis to anti-tumor effect. In this paper, methylation inhibitor decitabine treatment of hematological malignancies in the application are reviewed.

关 键 词：血液肿瘤 地西他滨 甲基化 

分 类 号：R733[医药卫生—肿瘤]